Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 5Gastrointestinal 5Lymphoid 4Other hematologic neoplasm 3Thoracic 2Plasma cell 2Head & Neck 2CNS 2Sarcoma 1Other solid neoplasm 1Dermatologic 1

Conditions

Multiple Myeloma 2Neoplasms 1Nausea 1Lymphoma 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Palonosetron × Plasma cell × Clear all
NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT00306735 2016-12-05

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Eisai Inc.

Phase 2 Completed
75 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡